K16 expression in uninvolved psoriatic skin: A possible marker of pre-clinical psoriasis

Journal of Cutaneous Pathology

Volumn 31, Issue 7, 2004, Pages 471-476

  Bhawan, Jag ^a   Bansal, Cheryl ^a   Whren, Kara ^a   Schwertschlag, Ullrich ^b   Bieber, T ^c   Carter, Eric ^d   Clark, Richard ^e   Gulliver, J Wayne P ^f   Miller, Bruce H ^g   Leonardi, Craig ^h   Lipsker, D ⁱ   Luger, T ^j   Papp, Kim ^k   Phillips, Tania ^a   Reitmo, S ^l   Vanscheidt, Wolfgang ^m   Weinberg, Jeffrey ⁿ  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF BONN   (Germany)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e STONY BROOK UNIVERSITY   (United States)

^f NewLab Clin Res Inc St John's   (United States)

^g OREGON MEDICAL RESEARCH CENTER   (United States)

^h Probity Medical   (United States)

ⁱ UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^j UNIVERSITY OF MÜNSTER   (Germany)

^k Probity Medical   (Canada)

^l Hosp for Skin and Allergic Diseases   (Finland)

^m UNIVERSITY OF FREIBURG   (Germany)

ⁿ ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CYTOKERATIN 1; PROTEIN K16; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BASAL CELL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FROZEN SECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; PSORIASIS; STAINING;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-1; KERATINS; MALE; MIDDLE AGED; PSORIASIS; SKIN;

EID: 3242811435     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0303-6987.2004.0220.x     Document Type: Article

References (40)

1. Stern RS. Psoriasis. Lancet 1997; 350: 349.
2. Lebwohl M. Psoriasis. Lancet 2003; 361: 1197.
3. Weiss RA, Eichner R, Sun TT. Monoclonal antibody analysis of keratin expression in epidermal diseases: a 48- and 56-kdalton keratin as molecular markers for hyperproliferative keratinocytes. J Cell Biol 1984; 98: 1397.
4. Trepicchio WL, Ozawa M, Walters IB, et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 1999; 104: 1527.
5. Krueger JG, Wolfe JT, Nabeya RT, et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 1995; 182: 2057.
6. Wawersik MJ, Mazzalupo S, Nguyen D, Coulombe PA. Increased levels of keratin 16 alter epithelialization potential of mouse skin keratinocytes in vivo and ex vivo. Mol Biol Cell 2001; 12: 3439.
7. Eichner R, Sun TT, Aebi U. The role of keratin subfamilies and keratin pairs in the formulation of human epidermal intermediate filaments. J Cell Biol 1986; 102: 1767.
8. Sun TT, Eichner R, Nelson WG, et al. Keratin classes: molecular markers for different types of epithelial differentiation. J Invest Dermatol 1983; 81: 109S.
9. Stadler R, Marcelo C, Voorhees J, Orfanos C. Effect of a new retinoid, arotinoid (Ro 13-6298), on in vitro keratinocyte proliferation and differentiation. Acta Derm Venereol 1984; 64: 405.
10. Rothberg S. The evaluation of keratin fractions in normal and abnormal epidermis. J Invest Dermatol 1960; 34: 197.
11. Skerrow D, Hunter I. Protein modifications during the keratinization of normal and psoriatic human epidermis. Biochim Biophys Acta 1978; 537: 474.
12. Levine M, McLeod A. Fibrous proteins of normal and abnormal human epidermis. Br J Dermatol 1979; 100: 401.
13. Baden HP, McGilvray N, Cheng CK, Lee LD, Kubilus J. The keratin polypeptides of psoriatic epidermis. J Invest Dermatol 1978; 70: 294.
14. Weiss R, Guillet G, Freedberg I, et al. The use of monoclonal antibody to keratin in human epidermal disease: alterations in immunohistochemical staining pattern. J Invest Dermatol 1983; 81: 224.
15. Sun T, Eichner R, Schermer R, Copper D, Nelson W, Weiss R. Classification, expression, and possible mechanisms of evolution of mammalian epithelial keratins: a unifying model. In: Levine A, Topp W, Vande Wonde G, Watson J, eds. Cancer Cell. Cold Spring Harbor New York: Cold Spring. Harbor Laboratory Press, 1984: 169.
16. Pang YY, Schermer A, Yu J, Sun TT. Suprabasal change and subsequent formation of disulfide-stabilized homo- and heterodimers of keratins during esophageal epithelial differentiation. J Cell Sci 1993; 104(part 3): 727.
17. de Mare S, Van Erp PE, van de Kerkhof PC. Epidermal hyperproliferation assessed by the monoclonal antibody Ks8.12 on frozen sections. J Invest Dermatol 1989; 92: 130.
18. Lavker R, Sun TT. Heterogeneity in epidermal basal keratinocytes: morphological and functional correlations. Science 1982; 215: 1239.
19. Swensson O, Langbein L, McMillan J, et al. Specialized keratin expression pattern in human ridged skin as an adaptation to high physical stress. Br J Dermatol 1998; 139: 767 19.
20. Gottlieb AB, Grossman RM, Khandke L, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol 1992; 98: 302.
21. de Mare S, de Jong E, van de Kerkhof PC. DNA content and Ks8. 12 binding of the psoriatic lesion during treatment with the vitamin D3 analogue MC903 and betamethasone. Br J Dermatol 1990; 123: 291.
22. Wilson C, Dean D, Lane E, Dawber R, Leigh I. Keratinocyte differentiation in psoriatic scalp: morphology and expression of epithelial keratins. Br J Dermatol 1994; 131: 191.
23. Leigh I, Navsaria H, Purkis P, McKay I, Bowden P, Riddle P. Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro. Br J Dermatol 1995; 133: 501.
24. Castelijns FA, Gerritsen M, van Vlijmen-Willems IM, van Erp PE, van de Kerkhof PC. The epidermal phenotype during initiation of the psoriatic lesion in the symptomless margin of relapsing psoriasis. J Am Acad Dermatol 1999; 40: 901.
25. McGuire J, Osber M, Lightfoot L. Two keratins MW 50,000 and 56,000 are synthesized by psoriatic epidermis. Br J Dermatol 1984; 111: 27.
26. de Mare S, de Jong E, van Erp P, van de Kerkhof PC. Markers for proliferation and keratinization in the margin of the active psoriatic lesion. Br J Dermatol 1990; 122: 469.
27. Wevers A, Arnold H, Bonnekoh B, Schulze H, Mahrle G. Increased expression of proliferation keratins K6 and K16 in unaffected skin in exacerbated psoriasis. Z Hautkr 1990; 65: 471.
28. Thewes M, Stadler R, Korge B, Mischke D. Normal psoriatic epidermis expression of hyperproliferation-associated keratins. Arch Dermatol Res 1991; 283: 465.
29. Woodcock-Mitchell J, Eichner R, Nelson W, Sun T. Immunolocalization of keratin polypeptides in human epidermis using monoclonal antibodies. J Cell Biol 1982; 95: 580.
30. Eto H, Hashimoto K, Kobayashi H, et al. Monoclonal antikeratin antibody: production, characterization, and immunohistochemical application. J Invest Dermatol 1985; 84: 404.
31. Goodfield M, Hull S, Holland D, et al. Investigations on the 'active' edge of plaque psoriasis: vascular proliferation precedes changes in epidermal keratin. Br J Dermatol 1994; 131: 808.
32. Kallioinen M, Koivukangas V, Jarvinen M, Oikarinen A. Expression of cytokeratins in regenerating human epidermis. Br J Dermatol 1995; 133: 830.
33. Huszar M, Gigi-Leitner O, Moll R, Franke W, Geiger B. Monoclonal antibodies to various acidic (type I) cytokeratins of stratified epithelia. Selective markers for stratification and squamous cell carcinomas. Differentiation 1986; 31: 141.
34. Moll R, Moll I, Franke W. Differences of expression of cytokeratin polypeptides in various epithelial skin tumors. Arch Dermatol Res 1984; 276: 349.
35. Yoshikawa K, Katagata Y, Kondo S. Relative amounts of keratin 17 are higher than those of keratin 16 in hair-follicle-derived tumors in comparison with nonfollicular epithelial skin tumors. J Invest Dermatol 1995; 104: 396.
36. Oliver A, Kaawich W, Mighoff E, Watt A, Abramovich D, Rayner C. The differentiation and proliferation of newly formed epidermis on wounds treated with cultured epithelial allografts. Br J Dermatol 1991; 125: 147.
37. Gerritsen M, van Erp P, van Vlijmen-Willems I, Lenders L, van de Kerkhof PC. Repeated tape stripping of normal skin: a histological assessment and comparison with events seen in psoriasis. Arch Dermatol Res 1994; 286: 455.
38. Castelijns F, Gerritsen M, van Erp P, van de Kerkhof PC. Immunohistochemical assessment of keratin 16 on paraffin-embedded sections of normal and hyperproliferative skin: monoclonal antibodies Ks8.12 and LL025 in a comparative study. Arch Dermatol Res 1999; 291: 59.
39. van Erp P, Rijzewijk J, Boezeman J, et al. Flow cytometric analysis of epidermal subpopulations from normal and psoriatic skin using monoclonal antibodies against intermediate filaments. Am J Pathol 1989; 135: 865.
40. Oestreicher JL, Walters IB, Kikuchi T, et al. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J 2001; 1: 272.